The global biomarkers market is expected to grow at a CAGR of 9.9% in the first half of the forecast period. In 2018, the largest sector of the market was biomarker discovery, which encompasses revenues for instruments and reagents, as well as the other costs associated with in-house biomarker research and development. This sector accounted for 48% of the global biomarkers market sector.
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 170-page report you will receive 104 charts– all unavailable elsewhere.
The 170-page report provides clear detailed insight into the global biomarkers market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global Biomarkers Market forecasts to 2029
• This report also breaks down the revenue forecast for the global biomarkers market by Product: • Consumables • Services • Software
• This report also breaks down the revenue forecast for the global biomarkers market by Sector: • Biomarker Services • Biomarker Diagnostics • Biomarker Discovery
• This report also breaks down the revenue forecast for the global biomarkers market by Type: • Safety Biomarkers • Efficacy Biomarkers • Validation Biomarkers
• This report also breaks down the revenue forecast for the global biomarkers market by Discipline: • Genomics • Proteomics • Bioinformatics • Other
• This report also breaks down the revenue forecast for the global biomarkers market by Therapeutic Indication: • Cancer • Cardiovascular Diseases • CNS • Autoimmune Diseases • Other
• This report provides individual revenue forecasts to 2029 for these regional and national markets: • North America: US, Canada • Europe: Germany, UK, France, Spain, Italy, Rest of Europe • Asia-Pacific: China, Japan, India, Australia, South Korea, Rest of APAC • Middle East & Africa: South Africa, Saudi Arabia, Rest of Middle East & Africa • Latin America: Brazil, Mexico, Rest of Latin America
• Our study gives qualitative analysis of the biomarkers market. It includes a SWOT and STEP Analysis.
• Our study discusses the selected leading companies that are the major players in the biomarkers industry. These companies are biomarker service providers, biomarker technology providers and biomarker diagnostic developers: • AB SCIEX • Agilent • Axela Inc • Caprion Proteomics • Charles River Laboratories • Critical Diagnostics • Epigenomics • Genomic Health • ICON plc • Laboratory Corporation of America Holdings • MDxHealth (formerly OncoMethylome) • Myriad Genetics • Oxford Gene Technology (OGT) • Pacific Biomarkers • Parexel • Proteome Sciences • QIAGEN • Quest Diagnostics • Quintiles IMS Holdings Inc • Thermo Fisher Scientific • Worldwide Clinical Trials (WWC) • WuXi PharmaTec
• Our study also discusses activities of the big pharmaceutical companies that are investing in biomarkers development through, for example, collaborations with CROs: • Pfizer • Novartis • Roche Diagnostics • Ventana Medical Systems • Merck & Co. • Sanofi • GSK • Abbott Laboratories • AstraZeneca
• Key questions answered by this report: • How is the biomarkers market evolving? • What is driving and restraining the biomarker market dynamics? • Which trends and developments will prevail? • How will the market shares of the regional markets change by 2029 and which geographical region will lead the market in 2029? • Who are the leading players and what are their prospects over the forecast period?
Visiongain’s study is intended for anyone requiring commercial analyses for the global biomarkers market. You find data, trends and predictions.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1 Biomarkers: World Market Overview
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Key Questions Answered by This Analytical Report Include
1.5 Who is this report for?
1.6 Methodology
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain
2. An Introduction to Biomarkers
2.1 Definition of a Biomarker
2.1.1 A Brief History of Biomarkers
2.1.2 The Importance of Biomarkers
2.2 Biomarker Discovery and Validation
2.3 Uses of Biomarkers
2.3.1 Assessing Drug Efficacy
2.3.2 Assessing Drug Safety
2.3.3 Companion Diagnostics
2.3.4 Therapeutic Importance of Biomarkers
2.3.5 Imaging Biomarkers
2.4 Biomarkers and Personalised Medicine
2.5 Biomarker Discovery
2.5.1 Genomics
2.5.2 Proteomics
2.5.3 Metabolomics
3.The World Biomarkers Market Forecast to 2029
3.1 The World Biomarkers Market, 2018
3.1.1 The World Biomarkers Market: Overall Revenue Forecast to 2029
3.1.2 Lack of Investment and Reimbursement Issues May Restrain Market
3.2 The World Biomarkers Market by Product, 2018
3.2.1 The World Biomarkers Market by Product, 2018-2029
3.3 The World Biomarkers Market by Sector, 2018
3.3.1 The World Biomarkers Market by Sector, 2018-2029
3.4 The World Biomarkers Market by Type, 2018
3.4.1 The World Biomarkers Market by Type, 2018-2029
3.5 The World Biomarkers Market by Discipline, 2018
3.5.1 The World Biomarkers Market by Discipline, 2018-2029
4. Leading Disease Indications for Biomarker Discovery and Development: Forecast to 2029
4.1 The World Biomarkers Market by Disease Indication, 2018
4.2 The World Biomarkers Market: Overall Revenue Forecast by Indication, 2018-2029
4.3 Cancer Biomarker Market
4.3.1 A Brief History of Cancer Biomarker Research
4.3.2 The Current State of Cancer Biomarker Research
4.3.3 Companion Diagnostics for Cancer
4.3.4 Initiatives in Cancer Biomarker Research
4.3.4.1 Cancer Genome Atlas
4.3.4.2 The Early Detection Research Network
4.3.5 Many Cancer Diagnostics Are Reaching the Market
4.3.6 Opportunities and Challenges for Cancer Biomarkers
4.3.7 Cancer Biomarker Submarket: Revenue Forecast, 2018-2029
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
Visiongain Publishes Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031
We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
